Biotech Essentials

Biotech & Healthcare

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech Essentials

Top news of the week: 21.09.2021.

#stocks
#biotech
#COVID19
#NASH
#Media
#DigitalPathology

Healthcare

@JNJInnovation shared
On Sep 21, 2021
RT @JNJNews: New data confirm protection of our single-shot #COVID19 vaccine in the U.S. https://t.co/jbZqo5xySN The Janssen COVID-19 Vaccine has not been approved/licensed by FDA. https://t.co/Xnh5QY9N5o https://t.co/JYHTAJW5bL
Open
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in...

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in...

Additional data show a booster increases protection 94 percent protection in the U.S. with booster given at two monthsFour-fold increase in antibodies when given at two months 12-fold ...

@Biotechnology shared
On Sep 17, 2021
BioSpace Movers & Shakers, Sept. 17 https://t.co/ePfn4K5exL https://t.co/6tpc5mOZMg
Open
BioSpace Movers & Shakers, Sept. 17

BioSpace Movers & Shakers, Sept. 17

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

@Biotechnology shared
On Sep 16, 2021
Global Roundup: TreeFrog Scores $75 Million, Establishes US Toehold https://t.co/UtmwY80ZCK https://t.co/krMrtg08Wn
Open
Global Roundup: TreeFrog Scores $75 Million, Establishes US Toehold

Global Roundup: TreeFrog Scores $75 Million, Establishes US Toehold

Biopharma and life sciences companies and organizations from across the globe provide updates on their businesses and pipelines.

@SWLifeSciences shared
On Sep 20, 2021
Edessa Biotech Shares Rise 87% on Positive Findings in Phase 2 Monoclonal Antibody COVID-19 Study: https://t.co/JaOq7VRgrN $EDSA #biotech #stocks
Open
Edessa Biotech Shares Rise 87% on Positive Findings in Phase 2 Monoclonal Antibody COVID-19 Study

Edessa Biotech Shares Rise 87% on Positive Findings in Phase 2 Monoclonal Antibody COVID-19 Study

Edesa Biotech Inc. shares reached a new 52-week high after the company reported positive results from its Phase 2/3 monoclonal antibody study in hospitalized COVID-19 patients.

@SWLifeSciences shared
On Sep 15, 2021
French Biotech Firm Initiates Pivotal Phase 3 Study of Lanifibranor in 900 NASH Patients: https://t.co/oMAXwjh8Cb $IVA #NASH #biotech #stocks Inventiva Pharma @InventivaPharma https://t.co/V3gsJtZIau
Open
French Biotech Firm Initiates Pivotal Phase 3 Study of Lanifibranor in 900 NASH Patients

French Biotech Firm Initiates Pivotal Phase 3 Study of Lanifibranor in 900 NASH Patients

ROTH Capital Partners LLC advised in a research report that Inventiva S.A. has initiated enrollment in its highly anticipated pivotal Phase 3 Study of Lanifibranor in individuals diagnosed ...

@SWLifeSciences shared
On Sep 20, 2021
Innate Pharma Partner AstraZeneca Presents Positive Data From NSCLC Trial to European Conference: https://t.co/JycG1XJctY $IPHA $AZN
Open
Innate Pharma Shares Rise After AstraZeneca Presents Positive Data From NSCLC Trial to European Conference

Innate Pharma Shares Rise After AstraZeneca Presents Positive Data From NSCLC Trial to European Conference

Innate Pharma S.A. shares traded 38% higher after the company reported its development partner AstraZeneca Plc. reported positive interim results from its Phase 2 COAST Study to the ...

@BIODeutschland shared
On Sep 15, 2021
RT @Roche: Creating life-changing diagnostic tools for cancer patients requires collaboration between the brightest minds. Our open environment for #DigitalPathology encourages data exchange to support this joint effort. https://t.co/MsHxdUZKpH #Media $ROG $RHHBY https://t.co/VdSNtCaPCf
Open
Roche opens access to pathology imaging tools to improve patient care

Roche opens access to pathology imaging tools to improve patient care

Roche launches the Digital Pathology Open Environment, encouraging collaboration among software developers to improve patient outcomes and expand personalised healthcare through …

@MEDiSTRAVA_Cons shared
On Sep 16, 2021
RT @AnjariumBio: We are thrilled to announce that we have raised CHF55.5M ($61M) Series A to develop our next-generation non-viral gene therapies. The round was co-led by @Abingworthbio and @Gimv, alongside Omega Funds, Pfizer Ventures and Surveyor (a Citadel company) https://t.co/nYRvrw3VYx
Open
09.16.21 - Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies

09.16.21 - Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies

Anjarium’s versatile platform combines proprietary gene vectors, targeted non-viral delivery technologies and efficient manufacturing solutions to unlock the full potential of …

Read more: Healthcare
weekly 21.09.2021
View archives
Back to home

Subscribe to Biotech Essentials - Biotech & Healthcare.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech Essentials - Biotech & Healthcare.
Privacy Policy

Sign up for the weekly Biotech Essentials - Biotech & Healthcare newsletter

Never again miss anything or anyone that matter in Biotech Essentials

Sign up and receive the Biotech Essentials - Biotech & Healthcare weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy